{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:00:54Z","timestamp":1793779254061,"version":"4.6.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["nmcd-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.numecd.2017.10.011","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T18:51:06Z","timestamp":1508352666000},"page":"1108-1113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-7995","authenticated-orcid":false,"given":"A.","family":"Perlman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.N.","family":"Heyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Matok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Stokar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Muszkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3339-4408","authenticated-orcid":false,"given":"A.","family":"Szalat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2017.10.011_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes, Obes Metab"},{"key":"10.1016\/j.numecd.2017.10.011_bib2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2017.10.011_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2017.10.011_bib4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2017.10.011_bib5","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.2337\/dc16-2200","article-title":"Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media","volume":"40","author":"Heyman","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2017.10.011_bib6","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O 2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am J Physiol - Ren Physiol"},{"key":"10.1016\/j.numecd.2017.10.011_bib7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium\u2013Glucose cotransporter 2 inhibitors for type 2 diabetes","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2017.10.011_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and harms of sodium-glucose Co-Transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Storgaard","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2017.10.011_bib9","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials","author":"Tang","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2017.10.011_bib10","unstructured":"http:\/\/bioportal.bioontology.org\/ontologies\/MEDDRA?p=classes&conceptid=20000003."},{"key":"10.1016\/j.numecd.2017.10.011_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.numecd.2017.10.011_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.numecd.2017.10.011_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.12611","article-title":"Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system","author":"Raschi","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.numecd.2017.10.011_bib14","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.numecd.2017.10.011_bib15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.numecd.2017.10.011_bib16","article-title":"Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs","volume":"61","author":"Weber","year":"1984","journal-title":"Adv Inflamm Res"},{"key":"10.1016\/j.numecd.2017.10.011_bib17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","article-title":"Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration","volume":"24","author":"Hartnell","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.numecd.2017.10.011_bib18","series-title":"Data Min Appl Eng Med, InTech","first-page":"265","article-title":"Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS)","author":"Poluzzi","year":"2012"},{"key":"10.1016\/j.numecd.2017.10.011_bib19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","article-title":"Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS)","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.numecd.2017.10.011_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The weber effect and the United States food and drug Administration's adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.numecd.2017.10.011_bib21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.numecd.2017.10.011_bib22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.14740\/jocmr2849w","article-title":"Increased hematocrit during sodium-glucose Cotransporter-2 inhibitor therapy","volume":"9","author":"Heyman","year":"2017","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.numecd.2017.10.011_bib23","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2017.10.011_bib24","first-page":"317","article-title":"Postmarket safety events among novel therapeutics approved by the US food and drug administration between 2001 and 2010","volume":"2017","author":"Downing","year":"1854","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2017.10.011_bib25","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"376","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2017.10.011_bib26","first-page":"170","article-title":"Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure","volume":"42","author":"Mandal","year":"1994","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.numecd.2017.10.011_bib27","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet (London, Engl"},{"key":"10.1016\/j.numecd.2017.10.011_bib28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-8703(99)70009-8","article-title":"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)","volume":"138","author":"Knight","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2017.10.011_bib29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.numecd.2017.10.011_bib30","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475317302387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475317302387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T03:17:16Z","timestamp":1635823036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475317302387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0939475317302387"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2017.10.011","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2017.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}